For Black Americans, the battle with Chronic Myeloid Leukemia is marked by unique survival challenges and treatment ...

Acute myeloid leukemia (AML) is one of the most aggressive and genetically complex cancers, marked by the unchecked growth of ...

Triplet Regimen Yields Promising Response in Advanced-Phase Chronic Myeloid Leukemia Sep. 17, 2024 — According to new research, 80% of patients with previously untreated or relapsed/refractory ...

The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute ...

Acute myeloid leukemia is a type of cancer that starts inside bone marrow, the soft tissue inside bones that helps form blood cells. The cancer develops from myeloid blasts cells that would ...

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.

Despite the clear improvement in the treatment of patients with CLL achieved during the past few years, there is still a subset of patients who are refractory to therapy. Resistance to purine ...

Limited or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' ...

Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib ...

Biocon rose 1.08% to Rs 318.20 after the company said that Biocon Pharmahas received final approvals from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug applications (ANDAs) ...